AI for personalised combination drug treatment


AI for personalised combination drug treatment

  • August 15, 2018

A team of NUS researchers – including BIGHEART faculty Prof. Dean Ho – developed a new artificial intelligence (AI) platform that facilitates the design of combination drug therapy for the treatment of blood cancer patients. The platform, called Quadratic Phenotypic Optimisation Platform (QPOP), can optimise drug selection and dosage over time, without needing knowledge of which pathways to target, thus making combination therapy design faster, more personalised and efficient. 

Please click the link below for the research article: 

Please click the links below for the news articles: